Business Context and Reporting Period
Company: Revolution Medicines, Inc. (RVMD)
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2019
Business Overview: Revolution Medicines is a clinical-stage precision oncology company focused on developing targeted therapies for the RAS and mTOR signaling pathways. The company's most advanced asset is RMC-4630, a potent SHP2 inhibitor, which is being evaluated in Phase 1/2 clinical trials in collaboration with Sanofi. The company also maintains a preclinical pipeline of mutant-selective RAS(ON) inhibitors and other pathway inhibitors.
Key Financial Metrics
| Financial Metric (in thousands) | 2019 | 2018 | 2017 |
|---|---|---|---|
| Total Revenue | $50,041 | $20,165 | $0 |
| Research & Development Expenses | $91,755 | $51,084 | $26,586 |
| General & Administrative Expenses | $12,406 | $9,410 | $4,543 |
| Net Loss | $(47,664) | $(41,789) | $(31,127) |
| Cash, Cash Equivalents & Marketable Securities | $122,758 | $69,586 | $9,079 |
| Accumulated Deficit | $(157,386) | $(109,722) | $(67,933) |
Liquidity: As of December 31, 2019, the company held $122.8 million in cash and marketable securities. The company expects these funds, combined with proceeds from its February 2020 IPO ($251.0 million net), to fund operations for at least 12 months following the filing date.
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased by $29.9 million (148%) from 2018 to 2019. This was driven primarily by collaboration revenue from Sanofi, which rose from $19.4 million to $50.0 million due to increased reimbursable R&D costs for the SHP2 program advancing into clinical trials.
- Expense Increase: Operating expenses increased by $43.7 million (72%). Research and development expenses rose by $40.7 million (80%), attributed to the advancement of the SHP2 program into Phase 1b/2, the initiation of the SOS1 program, and increased third-party costs for RAS programs acquired via the Warp Drive acquisition.
- Net Loss: Net loss increased by $5.9 million to $47.7 million, reflecting the significant ramp-up in clinical development activities.
Guidance, Outlook, and Risks
Outlook and Strategy:
- RMC-4630 (SHP2 Inhibitor): The company is evaluating RMC-4630 as a backbone for combination therapies. Preliminary data from 63 patients in the Phase 1 monotherapy study and 8 patients in the Phase 1b/2 combination study (with cobimetinib) showed a manageable safety profile and evidence of anti-tumor activity in KRAS-mutant NSCLC. Intermittent dosing schedules are being prioritized over daily dosing due to better tolerability.
- RAS(ON) Pipeline: The company expects to nominate its first development candidate from its mutant-selective RAS(ON) portfolio (targeting KRAS G12C, G13C, G12D, and NRAS G12C) in 2020.
- Collaborations: Sanofi reimburses substantially all research costs and all development costs for the SHP2 program. The company retains 50% profit share and co-promotion rights in the U.S.
Risks and Contingencies:
- Capital Needs: The company has incurred losses since inception and expects to continue doing so. It will require substantial additional financing to complete clinical trials and commercialize products.
- Collaboration Dependency: The business is heavily dependent on the Sanofi collaboration. Sanofi can terminate the agreement for convenience, which would materially impact funding and development.
- Clinical Uncertainty: As a clinical-stage company with no approved products, there is significant risk that product candidates will fail to demonstrate safety or efficacy in later-stage trials.
- COVID-19 Impact: The pandemic has caused delays in patient enrollment and clinical site operations, though the company expects no material impact on clinical supply at the time of filing.
Key Facts for Investor Verification
- Revenue Source: Verify the sustainability of revenue, which is currently derived almost entirely from cost reimbursements under the Sanofi collaboration rather than product sales.
- Cash Runway: Confirm the post-IPO cash position ($122.8M year-end + $251M IPO proceeds) against the projected burn rate to validate the 12-month liquidity statement.
- Clinical Data: Review the preliminary Phase 1 data for RMC-4630, specifically the comparison of safety profiles between daily and intermittent dosing schedules, and the disease control rates in KRAS-mutant NSCLC patients.
- Sanofi Agreement Terms: Understand the termination rights held by Sanofi and the specific milestones required to trigger the remaining $520 million in potential payments.
- Intellectual Property: Assess the patent portfolio status, noting that while applications are pending, the company had no issued patents for the SHP2 program as of December 31, 2019 (a U.S. patent was granted in March 2020).